These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37419875)

  • 1. Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.
    Kouno T; Shibata S; Shigematsu M; Hyun J; Kim TG; Matsuo H; Wolf M
    Nat Commun; 2023 Jul; 14(1):4037. PubMed ID: 37419875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
    Letko M; Booiman T; Kootstra N; Simon V; Ooms M
    Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.
    Iwatani Y; Chan DS; Liu L; Yoshii H; Shibata J; Yamamoto N; Levin JG; Gronenborn AM; Sugiura W
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19539-44. PubMed ID: 19887642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
    Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
    J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
    Chesarino NM; Emerman M
    J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
    Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
    Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.
    Dang Y; Siew LM; Zheng YH
    J Biol Chem; 2008 May; 283(19):13124-31. PubMed ID: 18326044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
    Martin KL; Johnson M; D'Aquila RT
    J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
    Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
    Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatic disulfides as potential inhibitors against interaction between deaminase APOBEC3G and HIV infectivity factor.
    Yan X; Chen C; Wang C; Lan W; Wang J; Cao C
    Acta Biochim Biophys Sin (Shanghai); 2022 May; 54(5):725-735. PubMed ID: 35920198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3G: a double agent in defense.
    Smith HC
    Trends Biochem Sci; 2011 May; 36(5):239-44. PubMed ID: 21239176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
    Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
    J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
    Green LA; Liu Y; He JJ
    J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.
    Miyakawa K; Matsunaga S; Kanou K; Matsuzawa A; Morishita R; Kudoh A; Shindo K; Yokoyama M; Sato H; Kimura H; Tamura T; Yamamoto N; Ichijo H; Takaori-Kondo A; Ryo A
    Nat Commun; 2015 Apr; 6():6945. PubMed ID: 25901786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.